UseCases_ArguminSci_Discourse  

PubMed:20663046 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-212 DRI_Background denotes Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia.
T2 213-392 DRI_Outcome denotes We have shown that melatonin attenuated matrix metalloproteinase-9 (MMP-9) activation and decreased the risk of hemorrhagic transformation following cerebral ischemia-reperfusion.
T3 393-519 DRI_Outcome denotes Herein, we investigate the possible involvement of the plasminogen/plasmin system and endogenous MMPs inhibitor underlying the
T4 520-544 Token_Label.OUTSIDE denotes melatonin-mediated MMP-9
T5 545-556 DRI_Outcome denotes inhibition.
T6 557-652 DRI_Background denotes Mice were subjected to 1-hr ischemia and 48-hr reperfusion of the right middle cerebral artery.
T7 653-728 DRI_Background denotes Melatonin (5 mg/kg) or vehicle was intravenously injected upon reperfusion.
T8 729-791 DRI_Background denotes Brain infarction and hemorrhagic transformation were measured.
T9 792-886 DRI_Approach denotes Extracellular matrix damage was determined by Western immunoblot analysis for laminin protein.
T10 887-1025 DRI_Background denotes The activity and expression of MMP-2 and MMP-9 were determined by gelatin zymography, in situ zymography, and Western immunoblot analysis.
T11 1026-1173 DRI_Background denotes In addition, the activities of tissue and urokinase plasminogen activators (tPA and uPA) were evaluated by plasminogen-dependent casein zymography.
T12 1174-1373 DRI_Background denotes Endogenous plasminogen activator inhibitor (PAI) and tissue inhibitors of MMP (TIMP-1) were investigated using enzyme-linked immunosorbent assay (ELISA) and Western immunoblot analysis, respectively.
T13 1374-1488 DRI_Background denotes Cerebral ischemia-reperfusion induced increased MMP-9 activity and expression at 12-48 hr after reperfusion onset.
T14 1489-1725 DRI_Outcome denotes Relative to controls, melatonin-treated animals had significantly decreased MMP-9 activity and expression (P<0.05), in addition to reduced brain infarction and hemorrhagic transformation as well as improved laminin protein preservation.
T15 1726-1730 DRI_Outcome denotes This
T16 1731-1755 Token_Label.OUTSIDE denotes melatonin-mediated MMP-9
T17 1756-1896 DRI_Outcome denotes inhibition was accompanied by reduced uPA activity (P<0.05), as well as increased TIMP-1 expression and PAI activity (P<0.05, respectively).
T18 1897-1977 DRI_Challenge denotes These results demonstrate the melatonin's pluripotent mechanisms for attenuating
T19 1978-1996 Token_Label.OUTSIDE denotes postischemic MMP-9
T20 1997-2123 DRI_Challenge denotes activation and neurovascular damage, and further support it as an add-on to thrombolytic therapy for ischemic stroke patients.